Replies to post #74940 on Biotech Values

[iwfal]

it typically produces a mean of ~0.8 logs of viral reduction when used as monotherapy. (Source: various CC’s from such companies as GILD, ANDS, VRUS, and IDIX.)

Thanks! (But over what timeframe? ?) It must be published via posters, because it isn't anyplace obvious on pubmed. My next attempt would be to find it by looking at the cites in some of the earliest ifn/rib combo trials (e.g. the Lancet published trial)

[tony111]

Even though Ribaviran monotherapy is not sufficient for SVR,it magically normalizes liver ALT.